Literature DB >> 9667680

Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II.

P Grosjean1, G Wagnieres, C Fontolliet, H van den Bergh, P Monnier.   

Abstract

Photodynamic therapy (PDT) for cancer in the oesophagus and bronchi with red (630 nm) light may occasionally lead to wall perforation and fistula. Therefore, we investigated the clinical use of a less penetrating wavelength (514 nm) for the curative treatment of nine superficial carcinomas in the oesophagus and bronchi after photosensitization with Photofrin II. Tumours without infiltration beyond the submucosa in the oesophagus and beyond the lamina propria in the bronchi were considered as superficial cancers. The outcome and complications were compared with those of 13 superficial cancers treated with PDT and 630 nm light. In addition, we evaluated histologically the extent of the long-term tissue damage and scarring following treatment of six oesophageal cancers with either green or red light. At first endoscopic control, 7-10 days after PDT, tissue necrosis simply matched the illuminated area, without evidence of selective tumour damage. Six of nine tumours treated with 514 nm light had a complete response compared with nine of 13 after 630 nm irradiation. No perforation or fistula occurred in either treatment group. However, severe chest pain and fever with or without pleural effusion, consistent with occult perforation, were observed in three patients after 630 nm illumination in the oesophagus. Histologically, fibrous scarring in the three distinct sites treated with green light was limited to the superficial layers of the oesophagus. After red light treatment, transmural fibrosis with marked thinning of the oesophageal wall was evident in two of the three specimens available for inspection. These results indicate that PDT with 514 nm light has the potential to cure superficial cancer in the oesophagus and bronchi with essentially the same probability of success as red light. In the oesophagus, green light prevents deep tissue damage, thus reducing the risk of perforation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667680      PMCID: PMC2150371          DOI: 10.1038/bjc.1998.330

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Time constants in thermal laser medicine.

Authors:  M J van Gemert; A J Welch
Journal:  Lasers Surg Med       Date:  1989       Impact factor: 4.025

2.  Photodynamic therapy for early stage squamous cell carcinoma of the lung.

Authors:  D A Cortese; E S Edell; J H Kinsey
Journal:  Mayo Clin Proc       Date:  1997-07       Impact factor: 7.616

3.  In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues.

Authors:  B C Wilson; W P Jeeves; D M Lowe
Journal:  Photochem Photobiol       Date:  1985-08       Impact factor: 3.421

4.  Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.

Authors:  S G Smith; J Bedwell; A J MacRobert; M H Griffiths; S G Bown; M R Hetzel
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 5.  Photodynamic therapy in gastroenterology--current status and future prospects.

Authors:  S G Bown
Journal:  Endoscopy       Date:  1993-11       Impact factor: 10.093

6.  Canine bladder response to red and green light whole bladder photodynamic therapy.

Authors:  U O Nseyo; R K Whalen; S L Lundahl
Journal:  Urology       Date:  1993-04       Impact factor: 2.649

7.  Long-term survival after photodynamic therapy for esophageal cancer.

Authors:  A Sibille; R Lambert; J C Souquet; G Sabben; F Descos
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

8.  Endoscopic criteria of early squamous cell carcinoma of the bronchus.

Authors:  E Akaogi; I Ogawa; K Mitsui; M Onizuka; S Ishikawa; T Yamamoto; Y Inage; T Ogata
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

9.  Laser phototherapy following HpD administration in superficial neoplastic lesions.

Authors:  G Bandieramonte; R Marchesini; E Melloni; C Andreoli; S di Pietro; P Spinelli; G Fava; F Zunino; H Emanuelli
Journal:  Tumori       Date:  1984-08-31

10.  Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative.

Authors:  J C van Gemert; M C Berenbaum; G H Gijsbers
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

View more
  5 in total

1.  Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model.

Authors:  R Waksman; I M Leitch; J Roessler; H Yazdi; R Seabron; F Tio; R W Scott; R I Grove; S Rychnovsky; B Robinson; R Pakala; E Cheneau
Journal:  Heart       Date:  2006-01-06       Impact factor: 5.994

2.  Role of photodynamic therapy in the palliation of obstructing esophageal cancer.

Authors:  Hyeon Young Yoon; Young Koog Cheon; Hye Jin Choi; Chan Sup Shim
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

3.  Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane.

Authors:  Patrycja Nowak-Sliwinska; Judy R van Beijnum; Maaike van Berkel; Hubert van den Bergh; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2010-09-15       Impact factor: 9.596

4.  Harnessing photochemical internalization with dual degradable nanoparticles for combinatorial photo-chemotherapy.

Authors:  George Pasparakis; Theodore Manouras; Maria Vamvakaki; Panagiotis Argitis
Journal:  Nat Commun       Date:  2014-04-07       Impact factor: 14.919

5.  Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid.

Authors:  Izumi Kirino; Katsuhiko Fujita; Kei Sakanoue; Rin Sugita; Kento Yamagishi; Shinji Takeoka; Toshinori Fujie; Shinji Uemoto; Yuji Morimoto
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.